Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
-
One-Time gene therapy could change fabry disease treatment
Disease control CompletedThis study tested a new gene therapy called ST-920 for people with Fabry disease, a rare genetic condition. The therapy uses a harmless virus to deliver a working gene that helps the body produce an enzyme it's missing. 36 adults received a single intravenous dose and were follow…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Gene-Editing hope: could a One-Time transplant fix sickle cell?
Disease control CompletedThis early-stage study tested a new treatment called BIVV003 for adults with severe sickle cell disease. The approach uses a person's own blood stem cells, which are gene-edited in a lab and then given back after chemotherapy. The main goals were to see if the treatment is safe a…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:40 UTC